Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase

Hepatology Research

Volumn 42, Issue 1, 2012, Pages 33-41

  Kainuma, Mosaburo ^a   Furusyo, Norihiro ^a   Azuma, Koichi ^b   Kajiwara, Eiji ^g   Takahashi, Kazuhiro ^c   Nomura, Hideyuki ^d   Tanabe, Yuichi ^e   Satoh, Takeaki ^h   Maruyama, Toshihiro ⁱ   Nakamuta, Makoto ^f   Kotoh, Kazuhiro ^b   Shimoda, Shinji ^b   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

^d Shin Kokura Hospital   (Japan)

^e Fukuoka City Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^h Kokura Medical Center   (Japan)

ⁱ KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

Author keywords

Hepatitis C virus; Normal alanine aminotransferase; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 84055193435     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00907.x     Document Type: Article

References (35)

1. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. A relationship between the evaluation of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients. J Infect Dis 2000; 181: 1523-7.
2. Hayashi J, Ohmiya M, Kishihara Y etal. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-6.
3. Furusyo N, Hayashi J, Ohmiya M etal. Differences between interferon-alpha and-beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999; 44: 608-17.
4. Furusyo N, Hayashi J, Ueno K etal. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997; 19: 1352-67.
5. Kashiwagi K, Furusyo N, Kubo N etal. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003; 9: 333-40.
6. Hayashi J, Kishihara Y, Yamaji K etal. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C viral infection. Hepatology 1997; 25: 697-701.
7. Shiffman ML, Diago M, Tran A etal. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.
8. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
9. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
10. Tassopoulos NC. Treatment in patients with normal ALT levels. EASL International Consensus Conference on Hepatitis C: Consensus Statement. J Hepatol 1999; 30: 956-61.
11. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26: 133S-6S.
12. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
13. Puoti C, Castellacci R, Montagnese F etal. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.
14. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
15. Puoti C, Magrini A, Stati T etal. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
16. Zeuzem S, Diago M, Gane E etal. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
17. Puoti C, Pellicelli AM, Romano M etal. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-84.
18. Deuffic-Burban S, Babany G, Lonjon-Domanec I etal. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009; 50: 1351-9.
19. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
20. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
21. Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int 2010; 4: 723-31.
22. Furusyo N, Katoh M, Tanabe Y etal. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastroenterol 2006; 12: 784-90.
23. Furusyo N, Kajiwara E, Takahashi K etal. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-104.
24. Sandres-Sauné K, Abravanel F, Nicot F etal. Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. J Med Virol 2007; 79: 1821-6.
25. Sizmann D, Boeck C, Boelter J etal. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38: 326-33.
26. Furusyo N, Murata M, Ogawa E etal. Ribavirin concentration in the later stages of 48week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011; 66: 1127-39.
27. Hiramatsu N, Oze T, Yakushijin T etal. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009; 16: 586-94.
28. Kainuma M, Furusyo N, Kajiwara E etal. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.
29. Okanoue T, Itoh Y, Minami M etal. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 2008; 38: 27-36.
30. Hsu CS, Liu CH, Liu CJ etal. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J Gastroenterol Hepatol 2010; 25: 970-7.
31. Ramcharran D, Wahed AS, Conjeevaram HS etal. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat 2011; 18: 144-52.
32. Sangiovanni A, Morales R, Spinzi G etal. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27: 853-6.
33. Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634-43.
34. Ohmiya M, Hayashi J, Ueno K etal. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 2000; 45: 1953-8.
35. Lawson A. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat 2010; 17: 51-8.